Bupropion has been used successfully and safely for smoking cessation in adults. It was also used in very few studies among adolescent population. Our hypothesis is that Bupropion would be effective and safe among the adoelscent psychiatric population. A double-blind randomized controlled-trial will be held to determine that.

Psychiatric disorders in Axis I of DSM IV (38) (for the control group)

Smoking less than 6 cigarettes a day

Using other tobacco products other than cigarettes

Using any other smoking cessation treatment

Exhaled CO level of less than 10 ppm

Convulsive disorder or a history of seizures

A first-degree relative with a convulsive disorder

Past sensitivity to bupropion.

Positive pregnancy test

lactation

A lack of motivation to quit smoking

Alcohol and substance abuse (or current alcohol withdrawal)

Mental retardation and a lack of ability to give an informed consent

Concurrent use of Monoamine oxidase inhibitors (MAO-I).

Anorexia nervosa or bulimia nervosa.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00819078